Clinical Ink, the pioneering provider of eSource solutions for clinical trials, announced a merger with CentrosHealth, the ground-breaking provider of configurable mobile apps for clinical trial patient engagement and electronic patient reported outcomes (ePRO) founded by MPM Capital. The combination of Clinical Ink and CentrosHealth creates a world-class clinical trial technology platform differentiated by its ability to conduct truly ‘paperless’ clinical trials with purpose-built solutions for pharma companies, research sites, and patients.
Clinical Ink also announced that MPM Capital and F2 Ventures joined FCA Venture Partners and other existing investors to provide additional growth capital for Clinical Ink to aggressively expand operational capabilities and further development of the first truly paperless clinical trial platform. Clinical Ink additionally entered into a strategic partnership with Novartis Pharmaceuticals, as part of their Trials of the Future initiative, to help drive industry-wide adoption of fully electronic clinical trials.
Read the full press release here.